Duloxetine
Product Images NDC 65841-775

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 65841-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Healthcare Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Hydrochloride Delayed-release Capsules (Duloxetinecapsulemfg Figure 01)

Chemical structure of the active ingredient duloxetine, showing its molecular arrangement including a naphthalene ring, thiophene ring, and secondary amine with hydrochloride salt.*

FDA Label Image

Duloxetine Hydrochloride Delayed-release Capsules (Duloxetinecapsulemfg Figure 02)

A line graph comparing the percentage of patients improved by different doses of Duloxetine (60 mg twice daily, 60 mg once daily, 20 mg once daily) versus placebo, plotted against percent improvement in pain from baseline. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Duloxetine Hydrochloride Delayed-release Capsules (Duloxetinecapsulemfg Figure 03)

A line graph depicting percentage improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. It compares three groups: Duloxetine 60mg once daily (QD), Duloxetine 60mg twice daily (BID), and a placebo group, showing patient improvement trends across increasing pain reduction percentages.*

FDA Label Image

Duloxetine Delayed-release Capsules, 20 mg (Duloxetinecapsulemfg Figure 04)

Duloxetine Delayed-Release Capsules, USP 20 mg blister pack label by Cadila Healthcare Limited. The label includes dosage strength, quantity of 30 capsules, NDC 65841-774-06, storage instructions, pharmacist dispensing information, and manufacturer details indicating production in Ahmedabad, India.*

FDA Label Image

Duloxetine Delayed-release Capsules, 30 mg (Duloxetinecapsulemfg Figure 05)

Duloxetine delayed-release capsules, USP 30 mg by Cadila Healthcare Limited. The label indicates each capsule contains 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine, with a package of 30 capsules. Storage instructions note 20° to 25°C (68° to 77°F) and keeping the container tight. The label includes a barcode, lot, expiration, and revision date fields.*

FDA Label Image

Duloxetine Delayed-release Capsules, 60 mg (Duloxetinecapsulemfg Figure 06)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Cadila Healthcare Limited. The label shows the ZyGenerics brand and NDC 65841-776-06. It indicates that each delayed-release capsule contains 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine. The package contains 30 capsules and includes storage instructions of 20° to 25°C. The label advises dispensing with a medication guide and is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.